Free Trial

Catalent (CTLT) Competitors

$54.82
+0.17 (+0.31%)
(As of 05/24/2024 ET)

CTLT vs. RDY, ELAN, LEGN, SRPT, UTHR, CERE, ASND, VKTX, ITCI, and VTRS

Should you be buying Catalent stock or one of its competitors? The main competitors of Catalent include Dr. Reddy's Laboratories (RDY), Elanco Animal Health (ELAN), Legend Biotech (LEGN), Sarepta Therapeutics (SRPT), United Therapeutics (UTHR), Cerevel Therapeutics (CERE), Ascendis Pharma A/S (ASND), Viking Therapeutics (VKTX), Intra-Cellular Therapies (ITCI), and Viatris (VTRS). These companies are all part of the "pharmaceutical preparations" industry.

Catalent vs.

Dr. Reddy's Laboratories (NYSE:RDY) and Catalent (NYSE:CTLT) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, media sentiment, risk, valuation, community ranking, dividends and earnings.

Catalent received 323 more outperform votes than Dr. Reddy's Laboratories when rated by MarketBeat users. However, 59.25% of users gave Dr. Reddy's Laboratories an outperform vote while only 59.20% of users gave Catalent an outperform vote.

CompanyUnderperformOutperform
Dr. Reddy's LaboratoriesOutperform Votes
317
59.25%
Underperform Votes
218
40.75%
CatalentOutperform Votes
640
59.20%
Underperform Votes
441
40.80%

Dr. Reddy's Laboratories has a net margin of 19.97% compared to Dr. Reddy's Laboratories' net margin of -26.61%. Catalent's return on equity of 21.27% beat Dr. Reddy's Laboratories' return on equity.

Company Net Margins Return on Equity Return on Assets
Dr. Reddy's Laboratories19.97% 21.27% 15.44%
Catalent -26.61%-2.73%-1.06%

Dr. Reddy's Laboratories has a beta of 0.57, meaning that its stock price is 43% less volatile than the S&P 500. Comparatively, Catalent has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500.

Dr. Reddy's Laboratories has higher earnings, but lower revenue than Catalent. Catalent is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dr. Reddy's Laboratories$3.35B3.46$673.78M$4.0317.25
Catalent$4.28B2.32-$256M-$6.10-8.99

14.0% of Dr. Reddy's Laboratories shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Comparatively, 0.3% of Catalent shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Dr. Reddy's Laboratories currently has a consensus target price of $81.00, suggesting a potential upside of 16.50%. Catalent has a consensus target price of $53.14, suggesting a potential downside of 3.07%. Given Catalent's higher possible upside, analysts plainly believe Dr. Reddy's Laboratories is more favorable than Catalent.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dr. Reddy's Laboratories
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Catalent
1 Sell rating(s)
8 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.17

In the previous week, Catalent had 3 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 6 mentions for Catalent and 3 mentions for Dr. Reddy's Laboratories. Dr. Reddy's Laboratories' average media sentiment score of 1.45 beat Catalent's score of 1.23 indicating that Catalent is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Dr. Reddy's Laboratories
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Catalent
5 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Dr. Reddy's Laboratories beats Catalent on 11 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CTLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CTLT vs. The Competition

MetricCatalentPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$9.92B$6.80B$5.15B$17.80B
Dividend YieldN/A2.76%2.84%3.55%
P/E Ratio-8.999.78101.3822.25
Price / Sales2.32247.712,486.1010.27
Price / Cash16.8532.8735.8218.96
Price / Book2.755.705.365.91
Net Income-$256M$139.51M$106.36M$976.87M
7 Day Performance-0.99%-2.41%-1.27%-1.53%
1 Month Performance-1.77%2.29%3.24%3.68%
1 Year Performance48.64%-3.90%5.19%24.48%

Catalent Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RDY
Dr. Reddy's Laboratories
1.0714 of 5 stars
$68.92
+0.3%
$81.00
+17.5%
+27.1%$11.47B$279.16B17.1025,863Positive News
ELAN
Elanco Animal Health
3.0624 of 5 stars
$16.71
-1.7%
$18.29
+9.4%
+99.9%$8.26B$4.42B-6.319,300Insider Buying
News Coverage
LEGN
Legend Biotech
2.217 of 5 stars
$42.96
-5.4%
$82.74
+92.6%
-37.3%$7.83B$342.80M-33.051,800Analyst Forecast
Analyst Revision
News Coverage
SRPT
Sarepta Therapeutics
4.7553 of 5 stars
$129.12
-1.3%
$163.94
+27.0%
-6.0%$12.20B$1.24B1,173.821,314Options Volume
UTHR
United Therapeutics
4.8753 of 5 stars
$275.19
+0.2%
$309.44
+12.4%
+27.5%$12.21B$2.33B13.011,168Analyst Forecast
Insider Selling
Positive News
CERE
Cerevel Therapeutics
0.4439 of 5 stars
$41.77
-0.7%
$42.67
+2.1%
+24.9%$7.61BN/A0.00334
ASND
Ascendis Pharma A/S
1.1312 of 5 stars
$122.85
+1.5%
$176.88
+44.0%
+46.8%$7.15B$288.08M-12.78879Analyst Upgrade
VKTX
Viking Therapeutics
4.4635 of 5 stars
$64.23
-4.9%
$112.38
+75.0%
+187.1%$7.08BN/A-69.0628
ITCI
Intra-Cellular Therapies
4.7016 of 5 stars
$67.00
+2.6%
$90.17
+34.6%
+7.4%$7.07B$464.37M-57.76610Positive News
VTRS
Viatris
0.6662 of 5 stars
$10.96
-1.0%
$11.00
+0.4%
+15.3%$13.05B$15.43B-182.6738,000

Related Companies and Tools

This page (NYSE:CTLT) was last updated on 5/25/2024 by MarketBeat.com Staff

From Our Partners